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Objectives: The amino acid position 70 in HIV-1 reverse transcriptase (RT) plays an important role in
nucleoside RT inhibitor (NRTI) resistance. K70R is part of the thymidine analog mutations, but also other
amino acid changes have been associated with NRTI resistance, such as K70E and K70G. In this study, we
investigated the in vivo selection of the HIV-1 RT mutations K70S and K70T and their in vitro effect on drug
resistance and replication capacity.
Methods: Recombinant viruses with RT mutations were generated to measure the in vitro drug susceptibility
and replication capacity. Bayesian network analysis and three-dimensional modeling were performed to
understand the selection and impact of the RT70 mutations.
Results: K70S and K70T were found at a low frequency in RTI-experienced HIV-1 patients (0.10% and
0.20%). Baeyesian network learning identified no direct association with the in vivo exposure to any specific
RTI. However, direct associations of K70S with mutations within the Q151M-complex and of K70T with
K65R were observed. In vitro phenotypic testing revealed only minor effects of K70R/S/T as single
mutations, associated with Q151M and within the context of the Q151M-complex.
Discussion: These results suggest that the selection of K70S/T and their phenotypic impact are influenced
by the presence of other mutations in RT. However, the low impact on in vitro phenotype here observed,
alongside with the low in vivo prevalence, the exclusive direct association with known major RTI mutations
and the unknown correlation with in vivo response, do not yet necessitate the inclusion of K70S/T in drug
resistance interpretation systems.
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Introduction
Nucleoside reverse transcriptase (RT) inhibitors
(NRTIs) are analogs of deoxyribonucleosides that
lack the 39-hydroxyl group and cause chain termina-
tion during reverse transcription. NRTIs often
constitute the backbone of combination antiretro-
viral therapy (cART) in HIV-1 patients. Despite the
success of cART in reducing morbidity and mortal-
ity, its long-term activity can be compromised
because of drug resistance development. Resistance
to NRTIs generally occurs either by the excision or
by the exclusion/discrimination mechanism.1 The first
mechanism consists of an enhanced ATP-mediated
excision of the inhibitor at the dNTP binding site, as
initially observed for the thymidine analog zidovu-
dine (AZT) and typically caused by thymidine
associated mutations (TAMs). The TAMs confer
cross-resistance to most NRTIs and are associated
with hypersusceptibility towards foscarnet (PFA).
Second, resistance by exclusion consists of the
selective discrimination against NRTIs but still
allows incorporation of dNTPs, as described for
several mutations and the multi-NRTI drug resis-
tance pathway marked by Q151M.2
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Position 70 in RT plays an important role in NRTI
resistance development. Different mutations at this
position have been linked to resistance: K70R as
part of the TAM pathway enhances ATP-mediated
excision,3,4 and K70E induces resistance by lowering
maximum rate of inhibitor incorporation by RT and
antagonizes the TAM-mediated nucleotide excision.5
K70Q in the background of the multi-NRTI Q151M
mutation pathway results in a decreased binding
affinity of the inhibitor.6 Previously, we identified a
HIV-1 patient in which K70S emerged within the
context of the Q151M mutation pathway.7 This
mutation was substituted for K70T in subsequent
drug-free in vitro cultivation experiments.8 In this
study, we investigated the in vivo selection of K70S
and K70T and their impact on replication capacity
and RTI drug susceptibility: as single mutations,
associated with Q151M and within the context of the
Q151M-complex.
Materials and Methods
Patient information and in vivo drug resistance
profile
The identified patient received several sequential
mono- and bitherapies during the observation period
(Fig. 1). The polymorphic mutations A98S, I135T
and G196E were observed in a sample that was
isolated in 1992, after a short course of AZT and
interferon-a (IFN-a) that was followed by a long
episode of IFN-a monotherapy. In 1992, zalcitabine
(DDC) was initiated and was subsequently replaced
by didanosine (DDI). At that time, the mutations
S68G and Q151M could be detected, together with
two additional polymorphic mutations (V35I and
I178M). In 1993, the patient received a short episode
of AZTzDDI bitherapy which was soon interrupted
and followed by short courses of DDC and stavudine
(D4T) monotherapy. Three extra mutations from the
multi-nucleoside Q151M resistance pathway (V75I,
F77L and F116Y) and one extra polymorphism
(I202V) were developed in the sample that was
isolated 2 weeks after the start of D4T therapy.
Immediately before the initiation of the non-nucleo-
side reverse transcriptase inhibitor (NNRTI) loviride
(a-APA), a fourth isolate was available from which
the sequence was retrospectively determined, reveal-
ing the disappearance of V35I and the presence of the
mixture A62AV. During the selective pressure of
loviride and lamivudine (3TC), this mixture disap-
peared again and the NNRTI mutation K103N
together with the 3TC mutation M184V and a yet
uncharacterized K70S mutation were detected. The
K70S mutation was substituted for K70T in subse-
quent drug-free in vitro cultivation experiments.8
Cells and compounds
Human embryo kidney cells (293T) were purchased
from the ATCC (LGC Standard, Teddington, UK)
and cultivated in DMEM (Life Technologies, Gent,
Belgium) containing 10% fetal calf serum (FCS)
(Perbio Science, Erembodegem, Belgium), 20 mg/ml
gentamicin (Life Technologies) and 75 mM NaHCO3
(Life Technologies). U87.CD4 cells transfected with
CXCR4 and CCR59 were cultured in DMEM
supplemented with 15% FCS, 75 mM NaHCO3,
0.2 mg/ml geneticin (Life Technologies), 20 mg/ml
gentamicin and 1 mg/ml puromycin (Sigma-Aldrich,
Bornem, Belgium). Subcultivation was performed
every 2–3 days by digestion with trypsin/EDTA (Life
Technologies). MT-4 cells10 were grown in RPMI
1640 (Life Technologies) supplemented with 10%
FCS, 75 mM NaHCO3 2 mM glutamine (Life
Technologies) and 20 mg/ml gentamicin. All cell
cultures were maintained at 37uC in a humidified
CO2-controlled atmosphere.
Zidovudine (AZT), stavudine (D4T), didanosine
(DDI), lamivudine (3TC), abacavir (ABC) and
efavirenz (EFV) were obtained through the AIDS
Research and Reference Reagent Program (Division
of AIDS, NIAID, NIH). Tenofovir (TDF), raltegra-
vir (RAL) and AMD3100 were kind gifts of Gilead
Sciences (Foster City, CA, USA), Merck & Co
(Rahway, NJ, USA) and Anormed (Langley, BC,
Canada), respectively. Foscarnet (PFA) was pur-
chased from Sigma-Aldrich (Diegem, Belgium).
Plasmids
p83-2 containing the 59-part of the HIV-1 subtype B
strain NL4.3 (GenBank accession no. AF324493) was
used as starting material for site directed mutagen-
esis. This vector was obtained through the AIDS
Research and Reference Reagent Program (Division
of AIDS, NIAID, NIH from Dr Ronald
Desrosiers).11
The molecular clone used to generate recombinant
viruses was pNL4.3-DRT-EGFP (enhanced green
fluorescent protein). It displays a deletion between
Figure 1 History of therapy, evolution of CD4 count and RT
mutations (amino acids 1-259). AZT: zidovudine, IFN-a:
interferon a, DDC: zalcitabine, DDI: didanosine, D4T: stavu-
dine, 3TC: lamivudine, a-APA: loviride.
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RT codon 1 and 560 and contains the gene encoding
an EGFP between env and nef without affecting the
expression of any HIV gene.12
Site directed mutagenesis
The RT region was amplified from p83-2 using
PfuTurbo (Stratagene, Amsterdam, The Nether-
lands) and primers KVL098 and KVL099.12 The RT
amplicons were cloned into pCR-XL-TOPO plasmids,
using the TOPOH XL PCR Cloning Kit (Life
Technologies) and Escherichia coli DH5a-T1 compe-
tent cells (Life Technologies). Clones were randomly
picked and cultured. Subsequently, plasmid DNA was
isolated using QIAprep Spin Miniprep Kit (QIAgen,
Venlo, The Netherlands) and the RT region was
confirmed by sequencing.12 This plasmid was used for
the site directed mutagenesis experiments.
Mutations at position 62, 68, 70, 75, 77, 116, and
151 were introduced by extending primers containing
the desired mutations through thermocycling with
PfuTurbo (Stratagene), followed by digestion of the
template with DpnI (Fermentas, St. Leon-Rot,
Germany) and subsequent transformation in E. coli
DH5a-T1 competent cells. The following site-directed-
mutants (SDM) were constructed: K70R, K70S, K70T,
Q151M,Q151MzK70S, Q151MzK70T, A62V/S68G/
V75I/F77L/F116Y/Q151M (Q151M-complex), Q151M-
complexzK70S and Q151M-complexzK70T. Plasmid
DNA was extracted using QIAprep Spin Miniprep Kit
(QIAgen). The presence of the desired mutation and the
absence of additional mutations in the original back-
bone were confirmed by sequencing the entire RT region
as previously described.12
Generation of recombinant viruses
RT recombinant viruses containing the EGFP gene
were generated as previously described.12 Briefly, the
SDMs were amplified with the Platinum Pfx DNA
Polymerase (Life Technologies) and primers KVL098
and KVL099. The day before transfection 700 000
293T cells were subcultivated in small culture flasks
containing 5 ml DMEM for 293T cells. Two micro-
grams of purified PCR product (QIAquick PCR
Purification Kit, QIAgen) and 10 mg of purified
XbaI-digested pNL4.3-DRT-EGFP (PuriLink HiPure
Plasmid Filter Purification Kit, Life Technologies)
were co-transfected in these 293T cells using the
standard calcium-phosphate method. After overnight
incubation, medium was refreshed and 48 hours later,
the supernatant was transferred to freshly plated
U87.CD4.CXCR4.CCR5 cells. Cell cultures were
monitored for EGFP expression using fluorescence
microscopy. Virus supernatant was harvested by low
speed centrifugation and stored at 280uC for further
use. The RT sequence of the recombinant viruses
was confirmed.
Drug susceptibility testing
Drug susceptibility testing of the recombinant viruses
was performed as previously described.12 Briefly,
20 000 U87.CD4.CCR5.CXCR4 cells were infected
with the viruses in the presence of triplicate 5-fold
serial dilutions of the drugs (AZT, ABC, D4T, TDF,
DDI, 3TC, EFV, PFA and RAL) within a 96-well
tray. For AMD3100, infection was not carried out
until half an hour after the addition of the compound
to allow for interaction between AMD3100 with
CXCR4. Twenty-four hours post-infection, the per-
centage of EGFP-expressing cells was determined by
flow cytometry. EC50 was calculated according to
Reed and Muench for wild-type and recombinant
viruses in triplicate.13 The mean fold change (FC) and
the standard deviation (SD) were obtained from three
independent triplicate experiments. Two-sided one-
sample t-test, two-sample t-tests, Wilcoxon-signed
rank test or Mann–Whitney test were performed as
appropriate. The statistical significance was set at
P,0.05. All data were analyzed using GraphPad
Prism version 5.01 for Windows (GraphPad
Software, San Diego, CA, USA).
Analysis of replication capacity
For the analysis of replication capacity, one million
exponentially growing MT-4 cells were infected with
recombinant virus (pre-diluted to achieve 0.1% of
EGFP-positive cells after 72 hours) in a total volume
of 500 ml. The testing was done in triplicate for each
virus in 24-well plates. After 4 hours, the remaining
virus was washed away with PBS and cells were
cultured in 2 ml of RPMI at 37uC. Seventy-two hours
after infection, the amount of cells in each triplicate
was normalized to 750 000 cells/ml and the removed
cells were fixed with 2% paraformaldehyde. This
procedure was repeated every 24 hours for the
following 72 hours (i.e. 96, 120, and 144 hours).
The percentage of EGFP-expressing cells was deter-
mined by flow cytometry. The amount of infected
cells was normalized to the percentage of infected
cells at 72 hours (day 0). The curves were fitted
exponentially and the resulting k-values (y5ekt) were
used as a measure of replication capacity.14 Two-
sided two-sample t-tests (P,0.05) were performed
using GraphPad Prism version 5.01 for Windows
(GraphPad Software).
Three-dimensional (3D) modeling
The crystal structures used for the generation of
molecular models (1RTD and 3KLE) were down-
loaded from the Protein Data Bank (PDB). For
1RTD, the nucleotide was removed and mutations at
position 70 were introduced using Chimera.15 The
structure for AZTTP was created using CS
ChemOffice (CambridgeSoft Corporation), and
saved as a mol2 file for import into AutoDock
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Tools 1.5.4.16 RT structures with mutations at
position 70 and AZTTP were prepared for docking
using AutoDoc Tools 1.5.4.: all hydrogens were
added, Gasteiger partial charges were assigned to
the protein and the small molecule, non-polar
hydrogens were merged with carbon atoms and
AD4 atom types were assigned.16 Flexible residue
files for K65, K70R/T, and R72 were generated in
AutoDock Tools, as well as rigid receptor files for the
remaining residues in the protein structures. Box
coordinates were positioned over the polymerase
active site. AZTTP was docked to mutant RT using
AutoDoc Vina, with an exhaustiveness of 100.17
Energy-minimized residue poses were overlaid using
the SuperPose protein superposition server.18
Bayesian network learning
A Bayesian network (BN) is a probabilistic model
that describes statistical independencies between
variables, with dependencies visualized in a directed
acyclic graph.19 Following a previously described
methodology, clinical data were pooled from the HIV
Drug Resistance Database (Stanford University, CA,
USA), the University Hospital Leuven (Belgium) and
Hospital Egaz Moniz (Lisbon, Portugal).19,20 The
analysis included viral isolates spanning the RT
region that were sampled from HIV-1 patients
receiving cART containing NRTIs6NNRTIs, with
at most 1 sequence selected from each therapy line of
a patient. The robustness of the network was assessed
with a non-parametric bootstrap using 100 replicates.
Results
In vivo emergence of mutations at position 70 in
RT
A search within a dataset of 15 845 sequences from
12 968 RTI-experienced HIV-1 patients revealed a
frequency of 19.1% K70R, 0.1%K70S and 0.2% K70T.
BNs were constructed to investigate interactions
between mutations at position 70, known (N)NRTI
resistance mutations and therapy experience. The
consensus network is shown in Fig. 2. BN analysis
revealed a direct positive association of the non-
polymorphic mutations within the Q151M-complex
(V75I, F77L, F116Y, and Q151M) with K70S but only
with a low bootstrap value. The mutation K70T was
directly associated with K65R. No direct connection
with a specific NRTI was observed for K70S/T.
Drug susceptibility of RT mutants
To investigate the effect of K70S and K70T muta-
tions on drug susceptibility, the mutations were
introduced into the NL4.3 backbone as single
mutants or in combination with either Q151M or
the Q151M-complex. The single TAM mutation
K70R was included in the experiments as a positive
control. Susceptibility to several NRTIs (AZT, D4T,
DDI, 3TC, ABC, TDF) was tested in a single cycle
assay using U87.CD4.CXCR4.CCR5 cells (Fig. 3).
As NRTI mutants are often characterized with
hypersusceptibility to PFA, this drug was also
included. The NNRTI EFV, the integrase inhibitor
RAL and the CXCR4 antagonist AMD3100 were
included as control drugs.
For the single mutants K70R, K70S and K70T
only minor changes in drug susceptibility towards
NRTIs were observed (Fig. 3A). Although the
biological relevance is uncertain, statistically signifi-
cant reduced susceptibilities were observed for K70R
towards AZT (1.726) and for K70T towards 3TC
(1.346). Surprisingly, statistically significantly incre-
ased susceptibilities were observed for K70S and
K70T towards EFV (0.506 and 0.556).
Q151M resulted in statistically significant low-level
resistance against AZT and DDI (2.16 and 3.846,
respectively) (Fig. 3B). The susceptibility levels
towards all NRTIs decreased for the entire Q151M-
complex (FC ranging between 2.26 and 26.46)
(Fig. 3C). The addition of K70S/T to Q151M did not
result into statistically significant changes in drug
susceptibility, except for a slightly lower susceptibility
against 3TC for Q151MzK70T (shift from 1.236 to
2.356) (Fig. 3B). In the context of Q151M-complex,
the addition of K70S/T resulted into a slightly higher
susceptibility to AZT (shift from 26.266 to 17.796
and 21.356, respectively) and PFA (shift from 0.96
to 0.56 and 0.46, respectively) and conferred a
slight reduction in the susceptibility to EFV (shift
from 1.726 to 2.916 and 3.006, respectively). The
addition of K70S/T to Q151M-complex did not
change significantly the susceptibility to other drugs.
The fold-changes towards the control drugs RAL
and AMD3100 ranged between 0.736 and 1.986, of
which some values were statistically significantly
different from wild-type.
Replication capacity of the RT mutants
To investigate the impact of the described mutations
and mutational patterns on the replication capacity,
growth kinetic experiments were performed in a drug-
free environment. Results for the different viruses are
shown in Fig. 4. A statistically significant improved
replication capacity was observed for K70S (k-value
of 2.56 versus 2.14 for wild-type NL4.3). The six
mutants with Q151M and Q151M-complex, dis-
played a replication capacity significantly impaired
compared to wild-type (k-values between 0.61 and
0.78). The addition of K70S and K70T did not
significantly impact the replication capacity of
Q151M and Q151M-complex.
3D modeling of the RT mutants
To gain insight into the phenotypic impact of
mutations at position 70 towards AZT and PFA,
3D models were constructed (only effects of K70R/T
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are visualized in Fig. 5). The positions of K65, K70
and R72 were analyzed in a crystal structure of a
ternary complex RT-dsDNA-AZTppppA’ (Fig. 5A).
The side chains of K70S/T are too short to interact
with bound ATP. Moreover, K70T would abrogate
the stabilizing effect of arginine on ATP binding.
In an attempt to assess the roles of K70R and K70S/T
in changing susceptibility to PFA, we modeled
these mutations using the structure of a ternary
RT-DNA-dNTP complex (Fig. 5B and C). The
Figure 2 Bayesian Network analysis. Most probable Bayesian network learned from RT sequences of RTI-treated patients
showing direct influences between major mutations previously associated with RTI resistance, mutations at position 70 and RTI
treatment. An arc represents a direct dependency between the corresponding variables. Arrows indicate a protagonistic direct
influence, whereas blunt ended arcs indicate an antagonistic direct influence. In the network graph, obvious strong
antagonistic direct influences between different amino acids at a single position and protagonistic influences between RTIs
were not shown. Network features (presence or absence of direct influence) with a bootstrap higher than 65% were considered
robust and shown as solid arcs or lack of arcs, respectively. Dashed arcs have bootstrap support over 35%. Mutation patterns
were defined as thymidine associated mutations (TAM): TAM1 (M41L, L210W or T215Y) and TAM2 (D67N, K219E or K219Q) and
as nucleoside analogue mutations (NAM) (V75I, F77L, F116Y or Q151M), with at least one mutation present.
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models predict that K70T results in a shift of R72
whereby the positioning of K65, K70T and R72
stabilize the interaction with bound PFA. This
conformation also stabilize the b and c phosphates
of docked AZT-TP. Modeling the interaction of
K70R and R72 reveals that K70R can stack against
R72, which alters contacts with the phosphates of an
incoming nucleotide, and by extension, with PFA.
Discussion
In a clinical sample obtained from an HIV-1 patient
we observed the acquisition of K70S in the presence
of the multi-NRTI Q151M mutation pathway.7 In
subsequent drug-free in vitro cultivation experiments
this mutation evolved to K70T.8 At the onset of this
in vitro study, only K70R and K70E were already
reported as mutations associated with resistance to
specific NRTIs.
Bayesian Network learning was applied on a public
dataset combined with data from Leuven and Lisbon.
K70S and K70T had a low prevalence in RTI-
experienced HIV-1 patients (0.1–0.2%), in contrast to
K70R that had a prevalence of 19.1%. K70S andK70T
were not directly associated with a particular drug,
indicating that they are probably secondary mutations
to the Q151M mutation pathway and K65R, respec-
tively. The direct association of K70S with multi-
NRTI resistance mutations was in agreement with its
in vivo selection in our patient.7 The results from the
BN learning largely confirmed the current scientific
consensus: e.g. direct associations between NVP and
EFV and specific NNRTI mutations (e.g. NVP and
Y181C andV106A/I; EFV andY188L), 3TC/FTC and
M184IV, ABC and TAM2 and Y115F, AZT/D4T and
TAM1, and TDF and K65R.
Some previously characterized associations at RT
position 70 were also captured by the Baeysian
Network approach (Table 1). A direct association
was detected between K70R, TAM and exposure to
AZT or D4T. The in vivo selection of K70E and
K70Q by TDF-containing therapy was also mapped
in the network. Additionally, arcs were observed
between M184IV and K70E/Q, potentially due to the
fact that 3TC and FTC are often part of the selecting
regimens.
Although the mutations K70S and K70T were
selected in a background already containing NRTI
Figure 4 Replication capacity of RT mutant viruses. Slope k
of regression curve log10 (fold replication capacity)5e
kt, time
t as intervals of 24 hours after 72 hours post-inoculation.
Each bar represents the mean slope k±standard deviation
from three independent experiments. *, ** and ***, signifi-
cantly different from the wild-type by two-sample t-test at
significance level P,0.05, ,0.01 and ,0.001, respectively. *[,
**[ and ***[, significantly different from each other by two-
sample t-test at significance level P,0.05, ,0.01 and ,0.001,
respectively.
Figure 3 Drug susceptibility of RT mutant viruses in a
single cycle assay. For each independent experiment, the
mean EC50 value of the mutant virus was compared to the
mean EC50 value of the wild-type virus from triplicates,
generating the mean fold change (FC). Each bar represents
the mean FC±standard deviation from at least three
independent experiments. The line at value 1 represents
the FC of the wild-type reference virus. *, ** and ***,
significantly different from the wild-type by one-sample t-
test or by the Wilcoxon-signed rank test (where appropriate)
at significance level P,0.05, ,0.01 and ,0.001, respectively.
*[, **[ and ***[, significantly different from each other by two-
sample t-test or by the Mann–Whitney test (where appro-
priate) at significance level P,0.05, ,0.01 and ,0.001,
respectively. Mutations were generated by site directed
mutagenesis within the parental sequence of NL4.3. (A)
single K70R, K70S and K70T mutants. (B) Q151M,
Q151MzK70S and Q151MzK70T mutants. (C) A62V/S68G/
V75I/F77L/F116Y/Q151M (Q151M-complex), Q151M-
complexzK70S and Q151M-complexzK70T mutants. AZT,
zidovudine; D4T, stavudine; DDI, didanosine; 3TC, lamivu-
dine; ABC, abacavir; TDF, tenofovir; PFA, foscarnet; EFV,
efavirenz; RAL, raltegravir; AMD3100, CXCR4 antagonist.
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resistance mutations, their impact as single mutation
was also investigated to define their individual
contribution to NRTI resistance. This revealed an
opposite effect in resistance against AZT and PFA
for K70R and K70S/T, respectively. Arginine slightly
decreased, whereas serine and threonine slightly
increased susceptibility levels for these drugs. This
effect in drug susceptibility was also observed within
the context of the Q151M-complex. Although changes
in drug susceptibility were observed with statistical
significance, neither arginine, serine, nor threonine
caused extensive changes in susceptibility to other
NRTIs when other drug resistance mutations were
absent. The addition of K70S/T to Q151M and to the
Q151M-complex did not substantially influence the
NRTI susceptibility profile, except for a minor redu-
ction in susceptibility towards 3TC for Q151Mz
K70T. The results of previous studies showed that the
individual contribution of mutations at RT position 70
to in vitro drug resistance were minor but that the
contribution towards 3TC and FTC in vitro drug
resistance was often more substantial than to other
NRTIs (Table 1).5,6,21–24
Mutations do not only confer resistance but can
also compensate for loss in viral fitness.25,26 Even
though we did observe a minor negative impact of
K70R on the replication capacity, as reported
previously, this was not significant in our analysis.27
K70S and K70T on the other hand, had a slightly
higher and comparable replication capacity than
wild-type virus. Both Q151M and Q151M-complex
had a strongly impaired replication capacity and this
could not be restored by the addition of K70S or
K70T.
In general, resistance to NRTIs can either involve
excision of the incorporated nucleotide analog, or
discrimination against the inhibitor at the level of
binding and/or incorporation.1 Recent structural
data suggested that K70R facilitates binding of
ATP that acts as a pyrophosphate donor in the
excision of incorporated AZT.4 Enzyme kinetic
studies have shown that K70E can diminish rates of
excision of AZT.5 In this case, repulsion between
K70E and the phosphates of ATP could diminish
binding of ATP. In the context of the Q151M-
complex, K70Q is responsible for resistance to TDF
by changes in the hydrogen bond binding pattern in
the polymerase active site of RT.6
Modeling studies were performed to gain insight
into the phenotypic impact of K70R and K70S/T
towards AZT and PFA. Superposition of the models
suggested that changes at position 70 can affect the
positioning of K65 and R72 that both interact with
the phosphate moieties of a bound nucleotide.
Mutation K70R induces a change of the positioning
of R72, leading to altered contacts with the phos-
phates of an incoming nucleotide and with PFA,
which could partly explain the reduction of in vitro
drug susceptibility to AZT and PFA. In contrast,
70S/T can form a hydrogen bond with the side chain
of K65. This rearrangement along with the lack of
stacking ‘unfreezes’ R72, and contacts between its
side chain and PFA appear to be possible under these
conditions. Although further analyses are required to
Figure 5 Possible effects of substitutions at position 70 in HIV-1 RT. (A) Positions of K65, K70R and R72 in the crystal
structure of a ternary RT-dsDNA-AZTppppA’ complex (PDB code 3KLE) are shown in green. Mutation of K70T would abrogate
the stabilizing effect of Arg on ATP binding. (B) Positions for K70, K65 and R72 in the crystal structure of a ternary RT-dsDNA-
dNTP complex (PDB code 1RTD) are shown in green. Mg2z ions are green spheres. Residue poses for the flexible docking of
AZT-TP to K70T RT and K70R RT are shown in cyan and magenta, respectively. The AZT-TP pose shown is that seen for the
docking simulation using the K70R structure generated from 1RTD. Modeled interactions between K65, K70T and R72 result in
a shift of R72 into a position that can stabilize the b and c phosphates of a docked AZT-TP molecule. The same effect can be
expected for bound PFA. (C) Stacking interactions between the guanidiniums of 70R and R72 diminish contacts with the
phosphates of AZT, resulting in a rearrangement of these groups. The coloring scheme and the AZT-TP pose used are the same
as in panel B.
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determine the molecular mechanisms by which amino
acid changes at position 70 affect NRTI suscept-
ibility, this model helps to explain the (increased)
susceptibility to PFA of K70S/T. Additionally, the
side chains of serine and threonine are too short to
facilitate binding of ATP which is required for the
excision of AZT and this might explain the (incre-
ased) susceptibility towards AZT and the preferential
selection of K70S/T within the background of
Q151M instead of TAMs.
The K70S/T mutations also slightly interfered with
NNRTI resistance. K70S and K70T alone induced an
increase in susceptibility towards EFV but in the
context of Q151M-complex they reduced the suscept-
ibility towards EFV. K70 is one of the residues within
the RT finger domain that folds over the incoming
dNTP or analog. How these amino acid changes can
impact the susceptibility to EFV is unclear as K70 is
not part of the NNRTI binding pocket. However,
the selection of NRTI resistance mutations by
NNRTI28,29 and the interference of NRTI resistance
mutations with in vitro NNRTI resistance have been
reported before.30,31 The role of K70 in in vivo
NNRTI resistance could be supported by the
observation that K70E/G/N/Q/S/T (not K70R) were
1.5 to 5 times more prevalent in NNRTI-experienced
patients than in NRTI-experienced patients who were
still NNRTI-naı¨ve.32
Collectively, our results and data from literature
showed that particular amino acid changes at
position 70 could make small contributions to RTI
drug susceptibility and that their in vivo selection and
in vitro impact could be influenced by drug exposure
and viral genetic background. However, the in vivo
clinical significance of these effects remains elusive.
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